Physician profile
Saagar Patel
NPI 1770746794
$638.25
in general payments reported to CMS, 2019-2025
19 companies · $89.54 in 2025
The $89.54 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.12 · 2020: $134 · 2021: $90.52 · 2022: $82.77 · 2023: $147 · 2024: $69.88 · 2025: $89.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $306.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $71.79 | 2020-2023 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $70.08 | 2023 | Gemtesa |
| Novo Nordisk INC | $63.51 | 2019-2022 | |
| Abbvie INC. | $57.48 | 2022-2024 | |
| Amgen INC. | $45.73 | 2020-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $42.52 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $37.10 | 2021-2023 | |
| Abiomed | $30.53 | 2025 | |
| Genentech USA, INC. | $27.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $26.00 | 2020 | |
| Pfizer INC. | $24.87 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $23.57 | 2020-2021 | |
| Sanofi Pasteur INC. | $22.83 | 2023 | |
| Sanofi-Aventis U.S. LLC | $22.80 | 2021 | |
| Amarin Pharma, INC. | $16.26 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.67 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $13.83 | 2025 | Rexulti |
| Lilly USA, LLC | $13.74 | 2024 | Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.43 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saagar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.